Debra BorchardtNovember 15, 2023
Even if Enveric receives regulatory approval for its compounds, it would still need funds for manufacturing.
Tag: Enveric Biosciences
Debra BorchardtNovember 15, 2023Debra BorchardtSeptember 20, 2023
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders. “Our EVM301 Series consists of small molecule therapies designed with the intent […]
John SchroyerAugust 14, 2023
The company said it progressed toward obtaining federal patents on synthetic psychedelic drugs.
Debra BorchardtJuly 24, 2023
Enveric Biosciences (NASDAQ: ENVB) announced the successful completion of preclinical ADME and toxicology studies for its lead candidate EB-373. EB-373 EB-373, is defined as a New Chemical Entity or NCE. According to the company it is designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary drug discovery platform to target anxiety […]
Debra BorchardtMay 15, 2023
The company will focus on psychedelics.
Debra BorchardtApril 4, 2023
The company is down to $14 million in working capital.
StaffApril 4, 2022
Enveric Biosciences (NASDAQ: ENVB), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces yet another filing of a provisional patent application based on new discoveries by the Company. This adds to their”Psybrary”. The application describes more than 100 novel individual molecules and, if the broadest claims are allowed, could protect more than 10,000 possible […]
Dave HodesJanuary 24, 2022
An emerging trend in some bioscience startups is the development of both cannabis and psychedelics products. One such company is Enveric Biosciences, headquartered in Naples, Florida, which hopes to leverage psychedelics-derived molecules for the mind and create synthetic cannabinoids for the body in the treatment of cancer. Enveric Biosciences focuses on synthesizing novel, tailored and […]
StaffDecember 15, 2021
Psychedelic biotech company Enveric Biosciences (NASDAQ: ENVB) announced the appointment of Bob Dagher, MD, as Chief Medical Officer, effective immediately. Robert Wilkins, MD, stepped down from his role of Chief Medical Officer on November 29th, 2021. Prior to joining Enveric, Dr. Dagher served as the Chief Medical Officer at WCG MedAvante-ProPhase where he led the clinical […]
Video StaffNovember 16, 2021
Green Market Report recently spoke with Enveric Biosciences (NASDAQ: ENVB) CEO Dr. Joseph Tucker at the Microdose Wonderland conference in Miami. Dr. Tucker sees room for both cannabinoids and psychedelics within the company. He also believes there are several areas for patients with needs that are currently unmet and Enveric looks to address those conditions.
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.